by Baker Heart & Diabetes Institute Pharmacological inhibition of EZH2 catalyzes pancreatic progenitor activation and β-cell maturation. The schematic outlines the progression from pancreatic multipotent progenitors to mature insulin-secreting β-cells, highlighting the regulatory target of EZH2 inhibitors, GSK126 and Tazemetostat. Credit: Signal Transduction and Targeted Therapy (2024). DOI: 10.1038/s41392-023-01707-xResearchers are zeroing in on the ultimate...